vs
Side-by-side financial comparison of BayCom Corp (BCML) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $20.4M, roughly 1.3× Sight Sciences, Inc.). BayCom Corp runs the higher net margin — 26.5% vs -20.4%, a 46.9% gap on every dollar of revenue. On growth, BayCom Corp posted the faster year-over-year revenue change (9.4% vs 6.9%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-2.0M). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs 2.9%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
BCML vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $20.4M |
| Net Profit | $6.9M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | 36.6% | -18.0% |
| Net Margin | 26.5% | -20.4% |
| Revenue YoY | 9.4% | 6.9% |
| Net Profit YoY | 12.1% | 64.9% |
| EPS (diluted) | $0.63 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $20.4M | ||
| Q3 25 | $25.7M | $19.9M | ||
| Q2 25 | $24.7M | $19.6M | ||
| Q1 25 | $24.3M | $17.5M | ||
| Q4 24 | $23.7M | $19.1M | ||
| Q3 24 | $25.6M | $20.2M | ||
| Q2 24 | $23.8M | $21.4M | ||
| Q1 24 | $24.5M | $19.3M |
| Q4 25 | $6.9M | $-4.2M | ||
| Q3 25 | $5.0M | $-8.2M | ||
| Q2 25 | $6.4M | $-11.9M | ||
| Q1 25 | $5.7M | $-14.2M | ||
| Q4 24 | $6.1M | $-11.8M | ||
| Q3 24 | $6.0M | $-11.1M | ||
| Q2 24 | $5.6M | $-12.3M | ||
| Q1 24 | $5.9M | $-16.3M |
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% | ||
| Q1 24 | — | 85.5% |
| Q4 25 | 36.6% | -18.0% | ||
| Q3 25 | 26.3% | -39.7% | ||
| Q2 25 | 35.3% | -59.6% | ||
| Q1 25 | 31.6% | -79.2% | ||
| Q4 24 | 34.2% | -62.5% | ||
| Q3 24 | 32.4% | -55.7% | ||
| Q2 24 | 31.9% | -59.2% | ||
| Q1 24 | 33.3% | -76.4% |
| Q4 25 | 26.5% | -20.4% | ||
| Q3 25 | 19.5% | -41.0% | ||
| Q2 25 | 25.8% | -61.0% | ||
| Q1 25 | 23.4% | -80.8% | ||
| Q4 24 | 25.9% | -62.1% | ||
| Q3 24 | 23.5% | -54.9% | ||
| Q2 24 | 23.6% | -57.7% | ||
| Q1 24 | 24.0% | -84.4% |
| Q4 25 | $0.63 | $-0.07 | ||
| Q3 25 | $0.46 | $-0.16 | ||
| Q2 25 | $0.58 | $-0.23 | ||
| Q1 25 | $0.51 | $-0.28 | ||
| Q4 24 | $0.55 | $-0.23 | ||
| Q3 24 | $0.54 | $-0.22 | ||
| Q2 24 | $0.50 | $-0.25 | ||
| Q1 24 | $0.51 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $338.6M | $63.9M |
| Total Assets | $2.6B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $92.0M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M | ||
| Q1 24 | — | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $338.6M | $63.9M | ||
| Q3 25 | $334.3M | $64.3M | ||
| Q2 25 | $330.6M | $70.0M | ||
| Q1 25 | $329.3M | $77.6M | ||
| Q4 24 | $324.4M | $87.5M | ||
| Q3 24 | $321.7M | $95.0M | ||
| Q2 24 | $315.3M | $101.6M | ||
| Q1 24 | $314.2M | $109.2M |
| Q4 25 | $2.6B | $115.3M | ||
| Q3 25 | $2.6B | $116.3M | ||
| Q2 25 | $2.6B | $122.0M | ||
| Q1 25 | $2.6B | $129.7M | ||
| Q4 24 | $2.7B | $142.8M | ||
| Q3 24 | $2.6B | $143.6M | ||
| Q2 24 | $2.6B | $149.7M | ||
| Q1 24 | $2.6B | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $-1.8M |
| Free Cash FlowOCF − Capex | $30.1M | $-2.0M |
| FCF MarginFCF / Revenue | 116.2% | -9.7% |
| Capex IntensityCapex / Revenue | 6.7% | 0.8% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $-1.8M | ||
| Q3 25 | $7.3M | $-8.7M | ||
| Q2 25 | $6.4M | $-7.5M | ||
| Q1 25 | $9.3M | $-11.6M | ||
| Q4 24 | $30.4M | $-3.5M | ||
| Q3 24 | $9.6M | $362.0K | ||
| Q2 24 | $7.7M | $-9.5M | ||
| Q1 24 | $5.1M | $-9.8M |
| Q4 25 | $30.1M | $-2.0M | ||
| Q3 25 | $6.2M | $-8.9M | ||
| Q2 25 | $5.6M | $-7.8M | ||
| Q1 25 | $9.1M | — | ||
| Q4 24 | $28.7M | $-3.6M | ||
| Q3 24 | $9.4M | $311.0K | ||
| Q2 24 | $7.4M | $-9.5M | ||
| Q1 24 | $3.9M | $-9.9M |
| Q4 25 | 116.2% | -9.7% | ||
| Q3 25 | 24.3% | -44.7% | ||
| Q2 25 | 22.8% | -39.6% | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 121.1% | -18.9% | ||
| Q3 24 | 36.6% | 1.5% | ||
| Q2 24 | 31.2% | -44.7% | ||
| Q1 24 | 16.1% | -51.4% |
| Q4 25 | 6.7% | 0.8% | ||
| Q3 25 | 4.3% | 0.9% | ||
| Q2 25 | 3.0% | 1.1% | ||
| Q1 25 | 0.6% | 0.0% | ||
| Q4 24 | 7.2% | 0.7% | ||
| Q3 24 | 1.0% | 0.3% | ||
| Q2 24 | 1.0% | 0.4% | ||
| Q1 24 | 4.7% | 0.6% |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCML
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
